TrialInfluenza and other respiratory viruses2023

Safety and efficacy of AK0529 in respiratory syncytial virus-infected infant patients: A phase 2 proof-of-concept trial.

Li-Min Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.